Marché nord-américain de l’infection par le virus de l’hépatite Delta (VHD) – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et perspectives du marché de l'infection par le virus de l'hépatite Delta (VHD) en Amérique du Nord

La prévalence croissante de l'hépatite, en particulier de l'hépatite B, influence considérablement le marché nord-américain de l'infection par le virus de l'hépatite Delta (VHD). L'hépatite D est une infection du foie causée par le virus de l'hépatite D (VHD), qui nécessite la présence du virus de l'hépatite B (VHB) pour se répliquer. À mesure que les infections par l'hépatite B augmentent au niveau régional, le nombre de personnes susceptibles d'être infectées par le VHD augmente également. Ce nombre croissant de personnes infectées par le VHB crée une population cible plus large pour le VHD, ce qui stimule la demande de solutions diagnostiques et thérapeutiques spécifiques au VHD.

Data Bridge Market Research analyse que le marché nord-américain de l'infection par le virus de l'hépatite Delta (HDV) devrait atteindre 9,49 millions USD d'ici 2031, contre 6,83 millions USD en 2023, avec un TCAC de 4,4 % au cours de la période de prévision de 2024 à 2031.

Définition du marché

Hepatitis Delta (HDV) infection is a rare but severe form of viral hepatitis that occurs when the Hepatitis Delta Virus (HDV) infects a liver already infected with Hepatitis B Virus (HBV). HDV is a defective virus that requires HBV to replicate and produce new viral particles, and it is characterized by its ability to rapidly cause liver disease, including acute hepatitis, liver failure, and even death. The coinfection of HBV and HDV leads to a more severe and rapid progression of liver disease compared to HBV infection alone, and it is often associated with higher levels of liver inflammation and fibrosis.

North America Hepatitis Delta Virus (HDV) Infection Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:      

Drivers

• Growing Prevalence of Hepatitis

The growing prevalence of hepatitis, particularly hepatitis B, is significantly influencing the North America Hepatitis Delta Virus (HDV) infection market. Hepatitis D is a liver infection caused by the Hepatitis D Virus (HDV), which requires the presence of the Hepatitis B Virus (HBV) to replicate. As hepatitis B infections increased regionally, the number of individuals susceptible to HDV infection also rises. This growing pool of HBV-infected individuals creates a larger target population for HDV, thus driving demand for diagnostic and therapeutic solutions specific to HDV.

• Increase in Healthcare Expenditure

The increase in healthcare expenditure has a significant impact on the growth of the North America Hepatitis Delta Virus (HDV) infection market by facilitating more substantial investment in diagnostic technologies and treatment options. As healthcare budgets expand, governments and healthcare organizations are able to allocate more resources towards advanced diagnostic tools for HDV. This investment leads to the development and deployment of more sensitive and accurate testing methods, which enhances early detection rates and drives up demand for diagnostic services. The improved availability of high-quality diagnostic tests contributes directly to market growth by increasing the overall testing and screening activities. Moreover, higher healthcare expenditure often translates into better access to and affordability of treatment options for HDV. As funding increases, there is greater potential for the development and distribution of innovative antiviral therapies and other medical interventions. This expanded access to effective treatments not only improves patient outcomes but also stimulates market growth by creating a more extensive patient base seeking treatment options. Enhanced therapeutic options can lead to better disease management and higher rates of treatment adherence, further boosting demand within the HDV infection market.

Opportunity

• Rising Innovative Drug Development

Pipeline therapies like JNJ-73763989 and Peginterferon Lambda are creating new opportunities for pharmaceutical companies to address the substantial unmet need for effective treatments in this space. JNJ-73763989 is a ground-breaking therapy designed to inhibit the replication of HDV by targeting essential components of the viral life cycle, offering a more precise and potentially effective approach compared to existing treatments. On the other hand, Peginterferon Lambda, a novel form of interferon therapy, is being evaluated for its ability to provide antiviral effects while minimizing the side effects traditionally associated with interferon-based treatments. Its targeted mechanism of action has the potential to improve patient outcomes by offering a more tolerable therapy option.

Restraint/Challenge

• Limited Awareness of Hepatitis Delta Virus (HDV)

Limited awareness of Hepatitis Delta Virus (HDV) infection is a significant restraint for the North America HDV infection market. Many healthcare providers and patients are not aware of the risks and consequences of HDV infection, leading to delayed diagnosis and treatment. This lack of awareness results in patients being diagnosed with liver disease at an advanced stage, making treatment more challenging and increasing the risk of complications and mortality.

• Side Effects of Current Treatments

Pegylated interferon-alpha has been a key therapeutic option for managing HDV due to its ability to induce a sustained viral response. However, its use is hampered by a range of debilitating side effects that can significantly impact patient adherence to the treatment regimen.

Common side effects of pegylated interferon-alpha include flu-like symptoms such as fever, chills, and muscle aches, as well as more severe issues such as fatigue, gastrointestinal disturbances, and psychological effects including depression and anxiety. These side effects can be distressing for patients, often leading to reduced quality of life and difficulty in maintaining consistent treatment. The severity of these adverse effects can discourage patients from completing their prescribed course of therapy, resulting in suboptimal treatment outcomes and potential disease progression.

Recent Developments

• In September 2024, Gilead Sciences, Inc. and Genesis Therapeutics have formed a strategic collaboration to discover and develop novel therapies using advanced AI-driven drug discovery technologies. This partnership aims to accelerate the creation of innovative treatments, enhancing Gilead's pipeline and strengthening its position in the competitive biopharma industry
• In March 2024, Gilead Sciences Inc. completed the acquisition of CymaBay Therapeutics, gaining access to innovative therapies for liver and rare diseases. This acquisition expands Gilead’s research portfolio and strengthens its pipeline, enhancing its capacity to address unmet medical needs. The acquisition of CymaBay provides Gilead with promising new drug candidates and expertise in liver and rare diseases, boosting its research capabilities and expanding its therapeutic offerings
• In March 2024, Gilead Sciences, Inc. and Merus have announced a collaboration to discover novel antibody-based trispecific T-cell engagers, aiming to enhance cancer immunotherapy. This partnership combines Gilead’s expertise with Merus’ innovative technology to develop advanced treatments for cancer
• In March 2024, Alnylam Pharmaceuticals launched the Family Health History Road Trip to promote discussions on hereditary ATTR (hATTR) amyloidosis. Genealogist Bernice Bennett traveled cross-country to highlight the importance of family health history for earlier diagnosis

North America Hepatitis Delta Virus (HDV) Infection Market Scope

The North America Hepatitis Delta Virus (HDV) infection market is segmented into nine notable segments based on type, treatment, drug type, route of administration, age group, gender, transmission, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

• Acute Hepatitis D
•  Chronic Hepatitis D

On the basis of type, the market is segmented into acute hepatitis D, chronic hepatitis D.

Treatment

• Surgery (Liver Transplant)
• Medication

On the basis of treatment, the market is segmented into surgery (liver transplant) and medication.

Drug Type

• Branded
• Generic

On the basis of drug type, the market is segmented into branded and generic.

Route of Administration

• Oral
• Parenteral

On the basis of route of administration, the market is segmented into oral and parenteral.

Age group

• Adults
•  Geriatric
•  Pediatric

On the basis of age group, the market is segmented into adults, geriatric, and pediatric.

Gender

• Female
•  Male

On the basis of gender, the market is segmented into female and male.

Transmission

• Contaminated Needles
•  Exposure to Infected Blood
•  Blood and Plasma Product Transfusion
•  Others

On the basis of transmission, the market is segmented into contaminated needles, exposure to infected blood, blood and plasma product transfusion and others.

End User

• Hospitals
•  Specialty Clinics
•  Home Care Setting
•  Research Institutes and Academic Centers
•  Ambulatory Surgical Centers
•  Others

On the basis of end user, the market is segmented into hospitals, specialty clinics, home care setting, research institutes and academic centers, ambulatory surgical centers, and others.

Distribution Channel

• Direct Tender
•  Retail Sales
• Others

Sur la base du canal de distribution, le marché est segmenté en appels d'offres directs, ventes au détail et autres.

Analyse/perspectives régionales du marché de l'infection par le virus de l'hépatite Delta (VHD) en Amérique du Nord

Le marché nord-américain de l’infection par le virus de l’hépatite Delta (HDV) est segmenté en neuf segments notables en fonction du type, du traitement, de la voie d’administration, de la forme posologique, du groupe d’âge, du sexe, de la transmission, de l’utilisateur final et du canal de distribution.

Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada et le Mexique.

Les États-Unis devraient dominer le marché européen de l’infection par l’hépatite Delta (HDV), en raison de leur importante population immigrée en provenance de pays à forte prévalence du VHB et du VHD, tels que la Chine, l’Asie du Sud-Est et les Caraïbes, qui sont plus susceptibles d’être porteurs du virus et de nécessiter un traitement pour une co-infection.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité de grandes entreprises de services et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des acteurs locaux et nationaux et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché de l'infection par le virus de l'hépatite Delta (VHD) en Amérique du Nord

Le paysage concurrentiel du marché de l'infection par l'hépatite Delta (HDV) en Amérique du Nord fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.

Certains des principaux acteurs du marché opérant sur le marché sont Gilead Sciences, Inc., Genentech, Inc., Eiger BioPharmaceuticals, Johnson & Johnson Services, Inc., Assembly Biosciences, Inc., PharmaEssentia Corporation, Vir Biotechnology, Inc., Huahui Health Ltd., Replicor, GlobeImmune Inc. et Alnylam Pharmaceuticals, Inc. entre autres.

SKU-72925